Concepedia

Leslie A. Andritsos

LA

95

Publications

7.4K

Citations

43

H-Index

2004

Active since

Affiliations

The Ohio State University(Current)

The Ohio State University Wexner Medical Center

The University of Texas MD Anderson Cancer Center

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Cornell University

Leslie A. Andritsos is an author at The Ohio State University specializing in medicine, immunology, and oncology.

ORCID

Top concepts

Publications per year

2004–2021

95

Publications

95

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 783 citations · Full text

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski et al. · JAMA Oncology · 2015 · 568 citations · Full text

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Sarah E.M. Herman, Amber Gordon, Amy J. Wagner et al. · Blood · 2010 · 541 citations · Full text

<i>BTK</i><sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn et al. · Journal of Clinical Oncology · 2017 · 461 citations · Full text

, , +14

Ibrutinib treatment improves T cell number and function in CLL patients

Meixiao Long, Kyle A. Beckwith, Priscilla Do et al. · Journal of Clinical Investigation · 2017 · 362 citations · Full text

Rows per page

1–5 of 95